Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07866703
Starting soon Observational

Thumb Muscle Activation During Different Activities of Daily Living in Thumb Base Osteoarthritis and Healthy Controls

NCT07866703 · tracked via the Priya Life Science Spain tracker
Sponsor
University of Malaga
Phase
Observational
Started
2026-09-26
Last updated
2026-10-08

Condition(s) studied

Trapeziometacarpal Osteoarthritis

Study summary

The aim of this study is to investigate whether there are differences in muscle activation of the first dorsal interosseous (FDI) and the abductor pollicis longus (APL) between individuals with and without thumb trapeziopometacarpal joint osteoarthritis (OA TMC) during the performance of activities of daily living (ADL).

The FDI muscle has been identified as a key stabilizer of the thumb TMC joint. However, scientific literature lacks information regarding the activation of the FDI and the APL during ADL, particularly in comparison with healthy individuals. OA TMC can lead to pain, reduced thumb strength, impaired hand function, and difficulty performing ADL. Determining whether differences in muscle activation patterns exist between individuals with and without OA TMC is crucial for understanding how this condition affects hand function and for guiding more specific and effective rehabilitation strategies.

Participants will perform six standardized functional tasks simulating everyday activities: turning a key to open, turning a key to close, picking up a coin, writing, squeezing a tube of toothpaste, and holding a glass of water. Muscle activity will be recorded using surface electromyography (sEMG) during all tasks.

Adults aged 30 years and older, both men and women, with thumb CMC osteoarthritis and healthy controls without osteoarthritis will be invited to participate.

Researchers will measure the activation patterns of the FDI and APL muscles during the ADL, with the aim of identifying differences between both groups and providing evidence to guide the rehabilitation of patients with thumb base osteoarthritis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Clinical diagnosis of thumb TMC osteoarthritis. * Healthy group:Participants with no history of musculoskeletal or neurological disorders affecting the dominant hand were included. Exclusion Criteria : * Presence of numbness, tingling, or other sensory disturbances * Upper limb entrapment neuropathy or cervical radiculopathy * History of neuromuscular disease, polyneuropathy, or plexopathy * Systemic diseases such as diabetes, hypothyroidism, or chronic liver or kidney disease * History of cancer, rheumatoid arthritis, active anticoagulation therapy, chemotherapy, or exposure to neurotoxins * Recent upper limb soft tissue or bone injury (trauma, fracture, or surgery of the arm or neck).

Primary outcome measure(s)

  • Surface electromyographic amplitude of the First Dorsal Interosseous muscle. — Day 1
    Mean surface electromyographic amplitude of the First Dorsal Interosseous muscle recorded during each of the 6 activities of daily living
  • Surface electromyographic amplitude of the Abductor Pollicis Longus muscle — Day 1
    Mean surface electromyographic amplitude of the Abductor Pollicis Longus muscle recorded during each of the 6 activities of daily living.

Trial sites (1)

FacilityCityRegionStatus
Universidad de Málaga Málaga Málaga

More University of Malaga trials in Spain

Morphological and Mechanical Assessment in the Achilles Tendon After Radiofrequency Stimulation in Runners Starting soon
Efficacy of Hyaluronic Acid Cream in Preventing Foot Ulceration Risk in Patients With Type 2 Diabetes and Moderate-to-Severe Peripheral Neuropathy: A Randomized Clinical Trial. Enrolling by invitation
Slow Breathing and Resistance Exercise in Fibromyalgia Enrolling by invitation
Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies. Enrolling by invitation
Foot and Ankle Strengthening Program to Improve Physical Function in Menopausal Women (FAMEX) Starting soon

Other trials for the same condition

Thumb Muscle Activation During First Dorsal Interosseous Activities of Daily Living in Thumb Base Osteoarthritis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07866703 on ClinicalTrials.gov ↗ ← All trials in Spain